heart-lung transplant

heart-lung transplant. A heart-lung transplant is a major surgical procedure where a patient's diseased heart and lungs are replaced with the healthy organs from a deceased donor. It is primarily considered for patients with end-stage, irreversible cardiopulmonary failure affecting both organ systems simultaneously. The procedure represents one of the most complex challenges in the field of transplant surgery and requires a highly coordinated multidisciplinary team.

Indications and patient selection

The primary indications include advanced pulmonary hypertension, particularly Eisenmenger syndrome, and complex congenital heart diseases with irreversible pulmonary vascular disease. Other conditions may include cystic fibrosis with severe cardiac involvement and end-stage lung disease combined with cardiomyopathy. Rigorous patient selection is conducted at major centers like Cleveland Clinic and Stanford University School of Medicine, evaluating factors such as age, functional status, and absence of other life-limiting illnesses. Contraindications typically include active infection, significant renal or hepatic dysfunction, and recent malignancy, as assessed by protocols from organizations like the International Society for Heart and Lung Transplantation.

Surgical procedure

The operation is performed under general anesthesia and requires the use of cardiopulmonary bypass to maintain circulation. A median sternotomy is performed to access the thoracic cavity. The recipient's heart and lungs are meticulously removed, with careful preservation of the phrenic nerve and recurrent laryngeal nerve. The donor bloc, procured and preserved by organizations like the United Network for Organ Sharing, is then implanted. Key anastomoses include the tracheal, aortic, and right atrial connections. Pioneering techniques were refined by surgeons such as Bruce Reitz at Stanford Hospital.

Post-operative care and complications

Immediate post-operative management occurs in an intensive care unit, focusing on hemodynamic stability and early mechanical ventilation weaning. Immunosuppressive regimens, often involving drugs like tacrolimus and mycophenolate mofetil, are initiated to prevent rejection. Major complications include primary graft dysfunction, acute rejection episodes monitored via endomyocardial biopsy, and opportunistic infections such as cytomegalovirus. Chronic complications encompass the development of bronchiolitis obliterans syndrome and side effects from long-term immunosuppression, including renal impairment and post-transplant lymphoproliferative disorder.

Outcomes and prognosis

According to registry data from the International Society for Heart and Lung Transplantation, survival rates are approximately 60% at five years post-procedure. Long-term prognosis is significantly influenced by the prevention and management of chronic lung allograft dysfunction and cardiac allograft vasculopathy. Quality of life studies, including those published in the Journal of Heart and Lung Transplantation, show significant functional improvement for many recipients. Ongoing care requires lifelong follow-up at specialized transplant centers and adherence to complex medication schedules.

History and development

The first long-term successful procedure was performed by a team led by Bruce Reitz at Stanford University Medical Center in 1981 on a patient with Eisenmenger syndrome. This built upon earlier experimental work in the mid-20th century, including pioneering research in immunosuppression with azathioprine and the development of cardiopulmonary bypass by John Gibbon. Subsequent decades saw advances in organ preservation solutions like University of Wisconsin solution and the introduction of more effective immunosuppressive agents such as cyclosporine, which improved outcomes. The field continues to evolve with research into ex-vivo lung perfusion and novel immunomodulatory therapies.

Category:Transplant surgery Category:Cardiothoracic surgery Category:Medical treatments